Floatz logo

Mylotarg

Infusions, Intravenous

Wyeth is now a wholly owned subsidiary of Pfizerantibody_drug_conjugatePhase 4 / ApprovedDormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Infusions, Intravenous cohort.

Asset / SponsorPhaseRating
Idarubicine
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4BB
Cytosin-Arabinosid
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4BB
FILGRASTIM
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4BB

Same molecule, other indications

Mylotarg is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
63 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
60 / 100
View asset →
acute promyelocytic leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →